Medicare Advantage Plans Linked to Lower Kidney Transplant Rates, Impacting Clinical Trial Enrollment

A new analysis in JAMA highlights a disparity in kidney transplant rates for patients with Medicare Advantage (MA) plans compared to traditional Medicare, suggesting that payer status is becoming a critical factor in clinical trial enrollment for end-stage kidney disease (ESKD). The study indicates that the omission of payer composition in site feasibility assessments may be hindering trial sponsors' enrollment efforts.